Aug 2026· British Journal of Clinical Pharmacology· 0 citations· 38 references
Medicine
TL;DR
In Chinese populations, hepatic impairment and CYP2C9 polymorphisms increased etrasimod exposure, with the greatest increase observed in CYP2C9 poor metabolizers with Child-Pugh C hepatic impairment (67% increase in AUCss).
Abstract
Aims
Etrasimod is an oral sphingosine-1-phosphate receptor modulator approved for moderate-to-severe ulcerative colitis. The impact of CYP2C9 polymorphisms and hepatic impairment on etrasimod exposure remains unclear. This study aimed to characterize their effects and identify clinically relevant dose adjustment strategies in Chinese patients.
Methods
A physiologically based pharmacokinetic model was developed and verified using in vitro metabolism and single-dose, multiple-dose and drug-drug interaction clinical pharmacokinetic data. The validated model was extrapolated to Chinese populations with different CYP2C9 genotypes and hepatic impairment severity to characterize exposure changes and optimize dosing.
Results
Most predicted pharmacokinetic parameters are within a twofold error range. At the approved dose of 2 mg once daily, the predicted median steady-state AUC0-24 and Cmax were 1976.95 ng·h/mL (95% prediction interval [PI]: 975.78-4144.29 ng·h/mL) and 98.40 ng/mL (95% PI: 52.9-190.51 ng/mL) in Caucasian subjects and 1988.82 ng·h/mL (95% PI: 814.91-4244.10 ng·h/mL) and 105.18 ng/mL (95% PI: 51.30-198.03 ng/mL) in Chinese subjects, respectively. In Chinese populations, hepatic impairment and CYP2C9 polymorphisms increased etrasimod exposure, with the greatest increase observed in CYP2C9 poor metabolizers with Child-Pugh C hepatic impairment (67% increase in AUCss).
Conclusions
CYP2C9 polymorphisms and hepatic impairment increased etrasimod exposure, particularly when combined. Model-based exposure matching supported dose reduction to 1.5 mg once daily for most affected subgroups and to 1 mg once daily for CYP2C9 poor metabolizers with Child-Pugh C hepatic impairment, providing quantitative support for individualized dosing.
Background/Objectives: Cefazolin is a first-generation cephalosporin antibiotic widely used for the treatment and prophylaxis of bacterial infections in both adult and pediatric populations. It is predominantly eliminated unchanged by the kidneys. Impaired renal function can reduce its clearance and increase systemic e...
A. Abdeen, Yousef A. Bin Jardan, Najia Rahim et al.· Pharmaceutics· 0 citations
PDA is a valuable translational biomarker for OAT-mediated clearance and is suggested to complement CLcr in characterizing meropenem clearance variability, establishing a key PD endpoint.
BACKGROUND AND OBJECTIVE
Understanding interindividual pharmacokinetic variability and potential for drug interactions is of clinical importance for pomalidomide given its long-term use in patients with relapsed and/or refractory multiple myeloma (RRMM). This study aimed to develop a physiologically based pharmacokinet...
Jeffry Adiwidjaja, A. Boddy, Andrew J. McLachlan· Clinical Pharmacokinetics· 0 citations
AIMS
Aildenafil citrate, an orally bioavailable phosphodiesterase type 5 (PDE5) inhibitor, is primarily metabolized by cytochrome P450 3A4 (CYP3A4). This study aimed to assess potential pharmacokinetic interactions between aildenafil citrate tablets and cytochrome P450 (CYP)3A modulators.
METHODS
This study involved...
Ran Xie, Nan Zhao, B. Jia et al.· British Journal of Clinical...· 0 citations
The authors' model predicts that ceritinib co-administration substantially elevates rivaroxaban exposure and exploratory major bleeding risk, and predicts model-predicted dosing strategies comparable to standard monotherapy.
Jian-Wei Ren, Yi-Yao Li, Xin Zheng et al.· European Journal of Pharmaco...· 0 citations
Background/Objectives: Despite its role as a first-line therapy for Thai people living with HIV (PLWH), dolutegravir (DTG) exhibits significant pharmacokinetic (PK) variability influenced by both genetic and non-genetic factors. This variability may contribute to an increased incidence of neuropsychiatric adverse event...
A. Chanruang, Angela K. Birnbaum, S. Illamola et al.· Pharmaceutics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.